Arch Biopartners Inc. focuses on developing novel drugs for acute kidney injury and organ damage. The company has a low market cap of $59.10M and a current price of $0.86, reflecting a 1.15% decline today. Concerns include a very low current ratio of 0.07, indicating liquidity issues, and a negative return on assets (ROA) of -90.9%, suggesting inefficiency in asset utilization. While the biotechnology sector has high growth potential, these financial metrics raise red flags regarding the company's short-term viability and operational effectiveness.
Loading financial metrics...
Company has $167K in cash but burned $343K last quarter. At this burn rate, only 0.5 quarters of runway remain without additional financing.
Company posted a loss of $-2.4M over the last year, representing -661.1% of revenue.
Debt of $2.4M is 14.6x the company's cash position of $167K.
Low debt-to-revenue ratio of -675.4% indicates conservative financial management.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2025-Q2 (June 30, 2025)